Moreover, both clinical prospective trials and retrospective studies have confirmed that patients with advanced relapsed/refractory MM harboring t(11;14) respond well to treatment with BCL-2 inhibitors, particularly venetoclax [6,7,8,9]. The gene discussed is BCL2; the disease is Miyoshi myopathy.